Radiopotentiation Profiling of Multiple Inhibitors of the DNA Damage Response for Early Clinical Development.
Molecular Cancer Therapeutics
Gill, Sonja J SJ; Wijnhoven, Paul W G PWG; Fok, Jacqueline H L JHL; Lloyd, Rebecca L RL; Cairns, Jonathan J; Armenia, Joshua J; Nikkilä, Jenni J; Lau, Alan A; Bakkenist, Christopher J CJ; Galbraith, Susan M SM; Vens, Conchita C; O'Connor, Mark J MJ
Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells.
Oncogene
Lloyd, Rebecca L RL; Wijnhoven, Paul W G PWG; Ramos-Montoya, Antonio A; Wilson, Zena Z; Illuzzi, Giuditta G; Falenta, Katarzyna K; Jones, Gemma N GN; James, Neil N; Chabbert, Christophe D CD; Stott, Jonathan J; Dean, Emma E; Lau, Alan A; Young, Lucy A LA
False-negative errors in next-generation sequencing contribute substantially to inconsistency of mutation databases.
Plos One
Kim, Young-Ho YH; Song, Yura Y; Kim, Jong-Kwang JK; Kim, Tae-Min TM; Sim, Hye Won HW; Kim, Hyung-Lae HL; Jang, Hyonchol H; Kim, Young-Woo YW; Hong, Kyeong-Man KM
pRAD50: a novel and clinically applicable pharmacodynamic biomarker of both ATM and ATR inhibition identified using mass spectrometry and immunohistochemistry.
British Journal Of Cancer
Jones, Gemma N GN; Rooney, Claire C; Griffin, Nicola N; Roudier, Martine M; Young, Lucy A LA; Garcia-Trinidad, Antonio A; Hughes, Gareth D GD; Whiteaker, Jeffrey R JR; Wilson, Zena Z; Odedra, Rajesh R; Zhao, Lei L; Ivey, Richard G RG; Howat, William J WJ; Harrington, Elizabeth A EA; Barrett, J Carl JC; Ramos-Montoya, Antonio A; Lau, Alan A; Paulovich, Amanda G AG; Cadogan, Elaine B EB; Pierce, Andrew J AJ
MEK inhibitors block growth of lung tumours with mutations in ataxia-telangiectasia mutated.
Nature Communications
Smida, Michal M; Fece de la Cruz, Ferran F; Kerzendorfer, Claudia C; Uras, Iris Z IZ; Mair, Barbara B; Mazouzi, Abdelghani A; Suchankova, Tereza T; Konopka, Tomasz T; Katz, Amanda M AM; Paz, Keren K; Nagy-Bojarszky, Katalin K; Muellner, Markus K MK; Bago-Horvath, Zsuzsanna Z; Haura, Eric B EB; Loizou, Joanna I JI; Nijman, Sebastian M B SM
Phenotypic consequences of somatic mutations in the ataxia-telangiectasia mutated gene in non-small cell lung cancer.
Oncotarget
Weber, Anika Maria AM; Drobnitzky, Neele N; Devery, Aoife Maire AM; Bokobza, Sivan Mili SM; Adams, Richard A RA; Maughan, Timothy S TS; Ryan, Anderson Joseph AJ
A Landscape of Pharmacogenomic Interactions in Cancer.
Cell
Iorio, Francesco F; Knijnenburg, Theo A TA; Vis, Daniel J DJ; Bignell, Graham R GR; Menden, Michael P MP; Schubert, Michael M; Aben, Nanne N; Gonçalves, Emanuel E; Barthorpe, Syd S; Lightfoot, Howard H; Cokelaer, Thomas T; Greninger, Patricia P; van Dyk, Ewald E; Chang, Han H; de Silva, Heshani H; Heyn, Holger H; Deng, Xianming X; Egan, Regina K RK; Liu, Qingsong Q; Mironenko, Tatiana T; Mitropoulos, Xeni X; Richardson, Laura L; Wang, Jinhua J; Zhang, Tinghu T; Moran, Sebastian S; Sayols, Sergi S; Soleimani, Maryam M; Tamborero, David D; Lopez-Bigas, Nuria N; Ross-Macdonald, Petra P; Esteller, Manel M; Gray, Nathanael S NS; Haber, Daniel A DA; Stratton, Michael R MR; Benes, Cyril H CH; Wessels, Lodewyk F A LFA; Saez-Rodriguez, Julio J; McDermott, Ultan U; Garnett, Mathew J MJ
The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo.
Oncotarget
Vendetti, Frank P FP; Lau, Alan A; Schamus, Sandra S; Conrads, Thomas P TP; O'Connor, Mark J MJ; Bakkenist, Christopher J CJ